Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30366790 | 0.86 | LMNA (0.75) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL30367009 | 0.80 | GAA (0.70) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL30366789 | 0.79 | LMNA (0.80) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL17792898 | 0.76 | LMNA (1.00) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL30938207 | 0.74 | LMNA (0.64) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL30366880 | 0.74 | LMNA (0.64) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL12857389 | 0.73 | HPGD (0.60) | GAALMNAL3MBTL1MAPTTSHR | |
| SCHEMBL14680354 | 0.72 | LMNA (0.60) | GAASMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL30366818 | 0.72 | LMNA (0.61) | GAASMN1; SMN2LMNASHMT2L3MBTL1 | |
| SCHEMBL30938206 | 0.71 | KDM4E (0.75) | GAASMN1; SMN2LMNASHMT2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235462-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM SCIENCES INC (KR) | 2025-07-24 | — | — | US | disclosed |
| EP-4416150-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM Sciences Inc (KR) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023063698-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM SCIENCES INC (KR) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235462-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | ZC3HAV1, GTF3C3, ZC3HAV1L | GAA 1080/4885SMN1; SMN2 2700/4885LMNA 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.